Strategic Blueprint LLC Takes $243,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Strategic Blueprint LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, HoldingsChannel reports. The firm purchased 438 shares of the company’s stock, valued at approximately $243,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. OFI Invest Asset Management bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. bought a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Valley National Advisers Inc. increased its stake in IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after purchasing an additional 22 shares in the last quarter. Altshuler Shaham Ltd bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $26,000. Finally, Geo Capital Gestora de Recursos Ltd bought a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $28,000. 87.84% of the stock is owned by institutional investors.

Insider Activity

In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 43,524 shares of company stock valued at $24,871,960. 2.11% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IDXX. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price for the company. in a research note on Tuesday, January 30th. Finally, The Goldman Sachs Group upped their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $591.50.

IDEXX Laboratories Trading Down 1.1 %

NASDAQ IDXX opened at $497.79 on Friday. The company has a market cap of $41.34 billion, a PE ratio of 49.43, a PEG ratio of 3.87 and a beta of 1.26. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The stock has a 50 day moving average of $546.90 and a 200-day moving average of $507.15.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.12 by $0.20. The company had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.05 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.